MICA and neoplasm: The released soluble MICA (sMICA) can bind to NKG2D and induce the downregulation and degradation of NKG2D in NK and T cells, reducing NKG2D-dependent effector functions, resulting in decreased cytotoxicity of these immune effector cells and facilitating tumour immune evasion [4, 14, 15].